Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib Solution for Inhalation (AP02) in Idiopathic Pulmonary Fibrosis (AURA-IPF)
NCT07194382Phase 2Recruiting
- Sponsor
- Avalyn Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of AP02 in idiopathic pulmonary fibrosis (IPF), sponsored by Avalyn Pharmaceuticals. Started Mar 2026; status: recruiting.
02
Drugs
AP02
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07194382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07194382.